Role of E-cadherins in development of lymphatic tumor emboli

Anita Gupta, Charuhas G. Deshpande, Sunil Badve

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

BACKGROUND. E-cadherin (E-cad) is a cell adhesion molecule that is expressed in normal breast tissue. While loss of E-cad expression is a characteristic feature of lobular carcinoma, it also is observed in infiltrating ductal carcinoma (IDC). The presence of peritumoral intralymphatic emboli also is a poor prognostic feature in IDC. Invasive lobular carcinoma rarely is associated with intralymphatic emboli. In the current study, the authors assessed E-cad expression in cases of IDC with and without intralymphatic tumor emboli to examine the potential role played by these molecules in the development of lymphatic emboli. METHODS. Fifty patients with high-grade invasive ductal carcinoma - 25 with prominent lymphatic invasion (LVI) and intralymphatic tumor emboli and 25 without LVI - were tested for expression of E-cad. For both groups, the intensity and frequency of E-cad expression was evaluated in tumor cells and lymphatic emboli; normal lobules were used as internal controls. RESULTS. Membranous expression of E-cad was observed in normal lobules and tumor cells in all patients, with the tumor cells exhibiting varying degrees of loss of expression. In the 25 LVI-positive patients, the majority of tumor cells (including intralymphatic emboli) expressed E-cad with an intensity and distribution similar to what was seen in normal lobules. In the LVI-negative patients, the intensity and the distribution of E-cad staining varied significantly. Tumor cells at the tumor-stroma interface showed a greater frequency and intensity of E-cad expression than did cells in the central region of the tumor. CONCLUSIONS. Strong expression of E-cad was observed in LVI-positive patients with high-grade IDC but not in LVI-negative patients. Emboli also exhibited high-intensity expression. These findings, taken in conjunction with the knowledge that intralymphatic tumor emboli in lobular carcinoma (which is E-cad-negative) are rare, suggest that E-cad plays an important role in tumor development and growth within the lymphatics.

Original languageEnglish
Pages (from-to)2341-2347
Number of pages7
JournalCancer
Volume97
Issue number9
DOIs
StatePublished - May 1 2003

Fingerprint

Cadherins
Embolism
Ductal Carcinoma
Neoplasms
Lobular Carcinoma
Cell Adhesion Molecules
Growth and Development
Breast
Staining and Labeling

Keywords

  • Breast cancer
  • E-cadherin
  • Intralymphatic emboli

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Role of E-cadherins in development of lymphatic tumor emboli. / Gupta, Anita; Deshpande, Charuhas G.; Badve, Sunil.

In: Cancer, Vol. 97, No. 9, 01.05.2003, p. 2341-2347.

Research output: Contribution to journalArticle

Gupta, Anita ; Deshpande, Charuhas G. ; Badve, Sunil. / Role of E-cadherins in development of lymphatic tumor emboli. In: Cancer. 2003 ; Vol. 97, No. 9. pp. 2341-2347.
@article{bf6bd9f814f44f54a0ed271b78bd89c2,
title = "Role of E-cadherins in development of lymphatic tumor emboli",
abstract = "BACKGROUND. E-cadherin (E-cad) is a cell adhesion molecule that is expressed in normal breast tissue. While loss of E-cad expression is a characteristic feature of lobular carcinoma, it also is observed in infiltrating ductal carcinoma (IDC). The presence of peritumoral intralymphatic emboli also is a poor prognostic feature in IDC. Invasive lobular carcinoma rarely is associated with intralymphatic emboli. In the current study, the authors assessed E-cad expression in cases of IDC with and without intralymphatic tumor emboli to examine the potential role played by these molecules in the development of lymphatic emboli. METHODS. Fifty patients with high-grade invasive ductal carcinoma - 25 with prominent lymphatic invasion (LVI) and intralymphatic tumor emboli and 25 without LVI - were tested for expression of E-cad. For both groups, the intensity and frequency of E-cad expression was evaluated in tumor cells and lymphatic emboli; normal lobules were used as internal controls. RESULTS. Membranous expression of E-cad was observed in normal lobules and tumor cells in all patients, with the tumor cells exhibiting varying degrees of loss of expression. In the 25 LVI-positive patients, the majority of tumor cells (including intralymphatic emboli) expressed E-cad with an intensity and distribution similar to what was seen in normal lobules. In the LVI-negative patients, the intensity and the distribution of E-cad staining varied significantly. Tumor cells at the tumor-stroma interface showed a greater frequency and intensity of E-cad expression than did cells in the central region of the tumor. CONCLUSIONS. Strong expression of E-cad was observed in LVI-positive patients with high-grade IDC but not in LVI-negative patients. Emboli also exhibited high-intensity expression. These findings, taken in conjunction with the knowledge that intralymphatic tumor emboli in lobular carcinoma (which is E-cad-negative) are rare, suggest that E-cad plays an important role in tumor development and growth within the lymphatics.",
keywords = "Breast cancer, E-cadherin, Intralymphatic emboli",
author = "Anita Gupta and Deshpande, {Charuhas G.} and Sunil Badve",
year = "2003",
month = "5",
day = "1",
doi = "10.1002/cncr.11332",
language = "English",
volume = "97",
pages = "2341--2347",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Role of E-cadherins in development of lymphatic tumor emboli

AU - Gupta, Anita

AU - Deshpande, Charuhas G.

AU - Badve, Sunil

PY - 2003/5/1

Y1 - 2003/5/1

N2 - BACKGROUND. E-cadherin (E-cad) is a cell adhesion molecule that is expressed in normal breast tissue. While loss of E-cad expression is a characteristic feature of lobular carcinoma, it also is observed in infiltrating ductal carcinoma (IDC). The presence of peritumoral intralymphatic emboli also is a poor prognostic feature in IDC. Invasive lobular carcinoma rarely is associated with intralymphatic emboli. In the current study, the authors assessed E-cad expression in cases of IDC with and without intralymphatic tumor emboli to examine the potential role played by these molecules in the development of lymphatic emboli. METHODS. Fifty patients with high-grade invasive ductal carcinoma - 25 with prominent lymphatic invasion (LVI) and intralymphatic tumor emboli and 25 without LVI - were tested for expression of E-cad. For both groups, the intensity and frequency of E-cad expression was evaluated in tumor cells and lymphatic emboli; normal lobules were used as internal controls. RESULTS. Membranous expression of E-cad was observed in normal lobules and tumor cells in all patients, with the tumor cells exhibiting varying degrees of loss of expression. In the 25 LVI-positive patients, the majority of tumor cells (including intralymphatic emboli) expressed E-cad with an intensity and distribution similar to what was seen in normal lobules. In the LVI-negative patients, the intensity and the distribution of E-cad staining varied significantly. Tumor cells at the tumor-stroma interface showed a greater frequency and intensity of E-cad expression than did cells in the central region of the tumor. CONCLUSIONS. Strong expression of E-cad was observed in LVI-positive patients with high-grade IDC but not in LVI-negative patients. Emboli also exhibited high-intensity expression. These findings, taken in conjunction with the knowledge that intralymphatic tumor emboli in lobular carcinoma (which is E-cad-negative) are rare, suggest that E-cad plays an important role in tumor development and growth within the lymphatics.

AB - BACKGROUND. E-cadherin (E-cad) is a cell adhesion molecule that is expressed in normal breast tissue. While loss of E-cad expression is a characteristic feature of lobular carcinoma, it also is observed in infiltrating ductal carcinoma (IDC). The presence of peritumoral intralymphatic emboli also is a poor prognostic feature in IDC. Invasive lobular carcinoma rarely is associated with intralymphatic emboli. In the current study, the authors assessed E-cad expression in cases of IDC with and without intralymphatic tumor emboli to examine the potential role played by these molecules in the development of lymphatic emboli. METHODS. Fifty patients with high-grade invasive ductal carcinoma - 25 with prominent lymphatic invasion (LVI) and intralymphatic tumor emboli and 25 without LVI - were tested for expression of E-cad. For both groups, the intensity and frequency of E-cad expression was evaluated in tumor cells and lymphatic emboli; normal lobules were used as internal controls. RESULTS. Membranous expression of E-cad was observed in normal lobules and tumor cells in all patients, with the tumor cells exhibiting varying degrees of loss of expression. In the 25 LVI-positive patients, the majority of tumor cells (including intralymphatic emboli) expressed E-cad with an intensity and distribution similar to what was seen in normal lobules. In the LVI-negative patients, the intensity and the distribution of E-cad staining varied significantly. Tumor cells at the tumor-stroma interface showed a greater frequency and intensity of E-cad expression than did cells in the central region of the tumor. CONCLUSIONS. Strong expression of E-cad was observed in LVI-positive patients with high-grade IDC but not in LVI-negative patients. Emboli also exhibited high-intensity expression. These findings, taken in conjunction with the knowledge that intralymphatic tumor emboli in lobular carcinoma (which is E-cad-negative) are rare, suggest that E-cad plays an important role in tumor development and growth within the lymphatics.

KW - Breast cancer

KW - E-cadherin

KW - Intralymphatic emboli

UR - http://www.scopus.com/inward/record.url?scp=0037403676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037403676&partnerID=8YFLogxK

U2 - 10.1002/cncr.11332

DO - 10.1002/cncr.11332

M3 - Article

VL - 97

SP - 2341

EP - 2347

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -